I agree beachhyena, also Slide 16, which is credited to the NWBio team at Flaskworks, is not just about GBM. It is also relevant to all or most solid tumor cancers.
DCVax-L is tumor and tissue agnostic, and the tumor lysate loaded dendritic cells will generate enhanced T Cell Stimulation and a Multiplier Effect (more T cell divisions),
This mechanism of action (MOA) is tissue agnostic, and will result in more late generation T cells to fight the cancer tumor, regardless of where the tumor(s) is/are located, or which specific organ(s) are affected (brain, colon, pancreas, lung, head & neck, etc.).
This also tells me how important it is for NWBio to complete all of the comparability tests and studies, so that Flaskworks devices can be incorporated into the DCVax-L production process, as soon as possible. When NWBio gets tissue agnostic approval for DCVax-L, Flaskworks devices will be the only way NWBio will be able to keep up with the DCVax-L demand for all or most solid tumor cancer patients around the world:
News 
Market Data 
Discover 
